Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

4023 - The accuracy of sentinel lymph node biopsy following neoadjuvant chemotherapy in clinically node positive breast cancer patients: A single institution experience

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Narges Sistany Allahabadi

Citation

Annals of Oncology (2018) 29 (suppl_8): viii58-viii86. 10.1093/annonc/mdy270

Authors

N. Sistany Allahabadi1, H. Yahyazadeh1, M. Hashemian1, M. Rajabpour1, S. Aminmozaffari1, M. Zaree1, A. Rezazadeh Mafi2

Author affiliations

  • 1 Milad General Hospital, Clinical Cancer Research Center, 111111111 - Tehran/IR
  • 2 Radiation oncology, Shahid Beheshti University of Medical Sciences, Teheran/IR
More

Resources

Abstract 4023

Background

Sentinel lymph node dissection (SLND) after neoadjuvant chemotherapy (NAC) is of questionable accuracy. In this study we evaluated the feasibility and accuracy of SLND in breast cancer patients with clinically positive axillary nodes.

Methods

We conducted a prospective cross-sectional study on breast cancer patients diagnosed at Milad Hospital of Tehran, Iran from June 2014 to February 2015. Biopsy-proven node positive patients who converted to clinically node-negative following NAC and had a successful SLND (more than three identified SLNs) were included in the study. We used a 2 × 2 contingency table to analyze the feasibility of SLNB (sensitivity, specificity, false negative ratio, and accuracy). STATA statistical software (version 13.0, StataCorp LP, Texas, USA) was used for statistical analysis.

Results

Among 52 patients who entered the study, 47 had a successful SLND (more than three identified SLNs) in whom we achieved a sensitivity of 100% (16/16), false-negative rate of 0% (0/21), a negative predictive value of 100% (16/16), and an overall accuracy of 89.4%.

Conclusions

SLND seems to be feasible and accurate in clinically lymph node positive breast cancer patients who achieve a clinically negative node status following neoadjuvant chemotherapy.

Clinical trial identification

Legal entity responsible for the study

Iran University of Medical Sciences.

Funding

Milad General Hospital - Iran National Social Security Organization.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings